| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/14/2014 | US8629118 Methods of treating a meiotic kinesin associated disease |
| 01/14/2014 | US8629117 Method for stimulating the immune system |
| 01/14/2014 | US8629116 Method for inducing a TRIF-bias |
| 01/14/2014 | US8629115 Compositions and methods for treating diseases |
| 01/14/2014 | US8629112 Template-fixed peptidomimetics with CXCR7 modulating activity |
| 01/14/2014 | US8629105 Pharmaceutical compositions for the treatment of movement disorders |
| 01/14/2014 | US8629102 3-hydroxyisothiazole 1-oxide derivatives |
| 01/14/2014 | US8629100 Method of inhibiting clostridium difficile by administration of oritavancin |
| 01/14/2014 | US8629099 Ophthalmic compositions comprising a dipeptide |
| 01/14/2014 | US8628807 Negatively charged polysaccharide derivable from aloe vera |
| 01/14/2014 | US8628799 Coated tablet formulation and method |
| 01/14/2014 | US8628798 Water-swellable polymers |
| 01/14/2014 | US8628796 Room-temperature stable dronabinol formulations |
| 01/14/2014 | US8628795 Transdermal therapeutic buprenorphine system |
| 01/14/2014 | US8628794 Palatable ductile chewable veterinary composition |
| 01/14/2014 | US8628793 NGNA compositions and methods of use |
| 01/14/2014 | US8628788 Formulations containing a non-oxidative biocide and a source of active halogen and use thereof in water treatment |
| 01/14/2014 | US8628761 Biodegradable polyurethane/urea compositions |
| 01/14/2014 | US8628759 Soft anticholinergic esters |
| 01/14/2014 | US8628756 Arginine heteromers for topical administration |
| 01/14/2014 | US8628754 Highly efficient delivery of a large therapeutic mass aerosol |
| 01/14/2014 | US8628751 Pyrazine derivatives for optical imaging and therapy |
| 01/14/2014 | CA2802133C Use of 5.alpha.-androstane(alkyl)-3.beta.,5,6.beta.-triol in preparation of neuroprotective drugs |
| 01/14/2014 | CA2760535C Vinyl indazolyl compounds |
| 01/14/2014 | CA2747055C Substituted benzimidazole derivatives as protein kinase inhibitors |
| 01/14/2014 | CA2746740C Purine compounds |
| 01/14/2014 | CA2746423C Aminopyrazole compounds as chki inhibitors |
| 01/14/2014 | CA2736130C Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use |
| 01/14/2014 | CA2721692C Triazine compounds as p13 kinase and mtor inhibitors |
| 01/14/2014 | CA2713673C Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation |
| 01/14/2014 | CA2701161C Lipid compositions for the treatment of gastro-intestinal disorders and the promotion of intestinal development and maturation |
| 01/14/2014 | CA2701025C Anti-bacterial pyrocatechols and related methods |
| 01/14/2014 | CA2669019C Oral care compositions containing combinations of anti-bacterial and host-response modulating agents |
| 01/14/2014 | CA2652443C 1- [ (4- [benzoyl (methyl) amino] -3- (phenyl) butyl] azetidine derivatives for the treatment of gastrointestinal disorders 1 |
| 01/14/2014 | CA2650798C Inhibitors of human immunodeficiency virus replication |
| 01/14/2014 | CA2649650C Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| 01/14/2014 | CA2646065C Disease modifying anti-arthritic activity of 2-methoxyestradiol |
| 01/14/2014 | CA2630714C S1p receptor modulating compounds and use thereof |
| 01/14/2014 | CA2628074C Aminodihydrothiazine derivative |
| 01/14/2014 | CA2624491C Novel azetidine compounds useful in the treatment of functional gastrointestinal disorders, ibs and functional dyspepsia |
| 01/14/2014 | CA2613792C Methods and compositions for the prevention and treatment of inflammatory disease |
| 01/14/2014 | CA2602234C Histamine h3 receptor agents, preparation and therapeutic uses |
| 01/14/2014 | CA2584286C 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
| 01/14/2014 | CA2578741C 1-alkoxy 1h-imidazo ring systems and methods |
| 01/14/2014 | CA2569678C Regulator of physiological function of ghrelin and use thereof |
| 01/14/2014 | CA2550929C Antiseptic compositions, methods and systems |
| 01/14/2014 | CA2528849C Quinoline derivatives as antibacterial agents |
| 01/14/2014 | CA2519875C Method of tumor regression with vegf inhibitors |
| 01/14/2014 | CA2490147C Liquid dosage forms of non-enterically coated proton pump inhibitors |
| 01/14/2014 | CA2439925C Hydrogels that undergo volumetric expansion in response to changes in their environment and their methods of manufacture and use |
| 01/14/2014 | CA2418088C Numb protein expression inhibitors by musashi 1 |
| 01/14/2014 | CA2370252C Cancer treatment with endothelin receptor antagonists |
| 01/14/2014 | CA2331343C Production of isoprenoid in recombinant yeast |
| 01/09/2014 | WO2014008477A2 Activation of trpv4 ion channel by physical stimuli and critical role for trpv4 in organ-specific inflammation and itch |
| 01/09/2014 | WO2014008469A2 Methods of treating arthritis |
| 01/09/2014 | WO2014008458A2 N-substituted benzamides and methods of use thereof |
| 01/09/2014 | WO2014008417A1 Deuterated vercirnon |
| 01/09/2014 | WO2014008407A1 Therapeutic bisphosphonates |
| 01/09/2014 | WO2014008375A1 Terminally modified polymers and conjugates thereof |
| 01/09/2014 | WO2014008366A2 Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid |
| 01/09/2014 | WO2014008361A2 Compositions comprising a sulforaphane or a sulforaphane precursor and milk thistle extract or powder |
| 01/09/2014 | WO2014008353A2 Compositions comprising sulforaphane or a sulforaphane precursor and a mushroom extract or powder |
| 01/09/2014 | WO2014008344A1 Method of treating retroviral infections and related dosage regimes |
| 01/09/2014 | WO2014008341A2 Compositions comprising sulforaphane or a sulforaphane precursor and magnesium |
| 01/09/2014 | WO2014008295A1 Manufacture of 2- (5- bromo-4 (-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid |
| 01/09/2014 | WO2014008285A1 Inhibitors of hepatitis c virus |
| 01/09/2014 | WO2014008270A1 Solid state form of vemurafenib choline salt |
| 01/09/2014 | WO2014008248A2 Compositions and methods for treating and inhibiting viral infections |
| 01/09/2014 | WO2014008223A2 Fatty acid synthase inhibitors |
| 01/09/2014 | WO2014008197A1 Heterocyclic modulators of lipid synthesis |
| 01/09/2014 | WO2014008159A1 Selective estrogen receptor degraders for treatment of tamoxifen resistant tumors |
| 01/09/2014 | WO2014007998A1 SORAFENIB DERIVATIVES AS p21 INHIBITORS |
| 01/09/2014 | WO2014007972A2 Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinphrine |
| 01/09/2014 | WO2014007853A1 Dihydromyricetin for the treatment of diseases and disorders of the glutamatergic system |
| 01/09/2014 | WO2014007781A2 Inhalation compositions |
| 01/09/2014 | WO2014007780A1 Orally-disintegrating formulations of dexketoprofen |
| 01/09/2014 | WO2014007779A1 Orally-disintegrating formulations of dexketoprofen |
| 01/09/2014 | WO2014007777A1 Combined capsule formulations of nsaids |
| 01/09/2014 | WO2014007776A1 Antispasmodic modified release formulations |
| 01/09/2014 | WO2014007775A1 A novel formulation having fast dissolution |
| 01/09/2014 | WO2014007774A1 Water soluble formulations comprising a piperidine derivative active agent |
| 01/09/2014 | WO2014007773A1 Compositions comprising muscarinic receptor antagonist and sorbitol |
| 01/09/2014 | WO2014007772A2 Inhalation compositions comprising glucose anhydrous |
| 01/09/2014 | WO2014007771A2 Inhalation compositions comprising muscarinic receptor antagonist |
| 01/09/2014 | WO2014007770A2 Inhalation compositions comprising corticosteroid and sorbitol |
| 01/09/2014 | WO2014007769A1 Compositions comprising muscarinic receptor antagonist and glucose anhydrous |
| 01/09/2014 | WO2014007768A1 Dry powder inhaler compositions comprising long acting muscorinic antagonists |
| 01/09/2014 | WO2014007767A1 Dry powder inhalers comprising a carrier other than lactose and a ternary component |
| 01/09/2014 | WO2014007766A1 Dry powder inhalers comprising a carrier other than lactose |
| 01/09/2014 | WO2014007650A1 Compounds and methods for selective imaging and/or ablation |
| 01/09/2014 | WO2014007636A1 Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour |
| 01/09/2014 | WO2014007635A1 Dietary fibre for use in the treatment of a gastro-intestinal side-effect of a nutrition or medicament |
| 01/09/2014 | WO2014007620A2 Oligonucleotide for the treatment of muscular dystrophy patients |
| 01/09/2014 | WO2014007606A1 Product for use in the prophylactic or therapeutic treatment of a negative emotion or introvert behaviour |
| 01/09/2014 | WO2014007597A1 Preparation for percutaneous absorption containing rotigotine |
| 01/09/2014 | WO2014007579A1 Transdermally absorbable preparation containing rotigotine |
| 01/09/2014 | WO2014007554A1 Method of preparing benzofuran derivative |
| 01/09/2014 | WO2014007549A2 Composition for preventing or treating colitis comprising s-allyl-l-cysteine as active ingredient, and medical preparation comprising same |
| 01/09/2014 | WO2014007463A1 Orally administered preparation whereby bioavailability of megestrol acetate is improved and method for improving bioavailability of orally administered megestrol acetate |
| 01/09/2014 | WO2014007447A1 Composition for preventing or treating diseases caused by angiogenesis, containing hydroxychalcone compound as active ingredient |